Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Steven G, Patten"'
Autor:
Gabrielle Monteith, Geraldine Higginson, Sarah E. Boston, Michelle L. Oblak, Steven G. Patten, J. Paul Woods
Publikováno v:
Veterinary Surgery. 41:430-435
Objective To assess survival times in dogs that received palliative radiation therapy (RT) alone, and in combination with chemotherapy, pamidronate, or both for primary appendicular bone tumors and determine whether the addition of these adjunctive t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7382aae5ff154bb29c6c3559782cbce1
https://doi.org/10.1111/j.1532-950x.2012.00968.x
https://doi.org/10.1111/j.1532-950x.2012.00968.x
Publikováno v:
Oncology. 81:126-134
Objective: Bevacizumab has promising activity against glioma, although reasons for poor efficacy and variable response rates in certain patients are unclear. Vascular endothelial growth factor receptor 2 (VEGFR2) is heterogeneously expressed within t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d92e13aa4a452380dc084372df18d9e7
https://doi.org/10.1159/000332849
https://doi.org/10.1159/000332849
Autor:
Michelle L, Oblak, Sarah E, Boston, Geraldine, Higginson, Steven G, Patten, Gabrielle J, Monteith, J Paul, Woods
Publikováno v:
Veterinary surgery : VS. 41(3)
To assess survival times in dogs that received palliative radiation therapy (RT) alone, and in combination with chemotherapy, pamidronate, or both for primary appendicular bone tumors and determine whether the addition of these adjunctive therapies a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::245ce4c66837efcd7bea41586f2f8868
https://pubmed.ncbi.nlm.nih.gov/23253085
https://pubmed.ncbi.nlm.nih.gov/23253085
Autor:
Kanwal Minhas, Karolina Skowronski, Steven G. Patten, Kristen Lacombe, Brenda L. Coomber, Una Adamcic
Publikováno v:
BMC Cancer
BMC Cancer, Vol 10, Iss 1, p 683 (2010)
BMC Cancer, Vol 10, Iss 1, p 683 (2010)
Background Targeting tumor vasculature is a strategy with great promise in the treatment of many cancers. However, anti-angiogenic reagents that target VEGF/VEGFR2 signaling have met with variable results clinically. Among the possible reasons for th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb9448bdbc3bb58a64204dbff64c5b36
http://europepmc.org/articles/PMC3009683
http://europepmc.org/articles/PMC3009683